Table 2 Features of participants to the different studies: all included subjects, all vaccine recipients, placebo recipients, and single vaccine recipients
N. of studies | N. of participants | Median female percentage; 25th-75th percentile (N. of studies) | Median age; 25th-75th percentile (N. of studies) | Median percentage of subjects with chronic conditions; 25th-75th percentile (N. of studies) | Median headache rank position among side effects; 25th-75th percentile (N. of studies) | |
|---|---|---|---|---|---|---|
All included subjects | 84 | 1,568,199 | 58.4%; 49.4–69.5% (N = 76) | 39.8; 35.5–49.9 (N = 62) | 37.2%; 18.2–92.5% (N = 19) | 3rd; 3rd-4th (N = 57) |
All Vaccines recipients | 84 | 1,522,830 | 59.4%; 49.1–71.1% (N = 72) | 41.0; 35.3–48.6 (N = 56) | 34.7%; 16.9–96.3% (N = 22) | 3rd; 3rd-4th (N = 56) |
BNT162b2 | 41 | 1,047,545 | 64.3%; 52.3–71.7% (N = 34) | 43.5; 38.2–57.3 (N = 26) | 85.0%; 39.4–100% (N = 9) | 3rd; 3rd-4th (N = 32) |
ChAdOx1 | 19 | 388,147 | 71.2%; 61.1–76.3% (N = 12) | 37.5; 35.8–49.7 (N = 8) | 45.8%; 41.5–50.1% (N = 2) | 4th; 3rd-4th (N = 12) |
PiCoVacc | 9 | 15,177 | 62.4%; 49.0%-67.7% (N = 6) | 35.8; 35.4–36.1 (N = 5) | 15.8%; 15.2–16.3% (N = 2) | 3rd; 2nd-3rd (N = 7) |
mRNA-1273 | 5 | 16,575 | 51.8%; 41.1–64.4% (N = 4) | 64.7; 48.9–66.7 (N = 3) | 100%; n.a (N = 1) | 3rd; 2nd-3rd (N = 3) |
NVX-CoV2373 | 3 | 7,612 | 48.8%; 48.7–49.0% (N = 2) | 56.0; n.a (N = 1) | n.r | 3rd; 2nd-3rd (N = 2) |
Placebo Recipients | 21 | 45,760 | 52.4%; 47.6–54.2% (N = 20) | 43.3; 37.6–48.1 (N = 19) | 13.8%; 4.8–26.9% (N = 5) | 3rd; 2nd-4th (N = 18) |